Tarsus Pharmaceuticals
TARS
92 hedge funds and large institutions have $387M invested in Tarsus Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 8 closing their positions.
391% more call options, than puts
Call options by funds: $329K | Put options by funds: $67K
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
164% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 14
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
54% more capital invested
Capital invested by funds: $252M → $387M (+$135M)
24% more funds holding
Funds holding: 74 → 92 (+18)
4.94% more ownership
Funds ownership: 75.04% → 79.98% (+4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$31.8M |
| 2 |
BlackRock
New York
|
+$11.8M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$3.1M |
| 4 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$2.62M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$15M |
| 2 |
DM
Deerfield Management
New York
|
-$14.5M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.05M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.78M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$1.43M |
TARS Hedge Fund Activity: Q2 2023 in Review
92 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q2 2023, worth a combined $387M — up 54% from $252M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TARS positions and 8 closed out — a net gain of 18 holders — while 37 added to existing stakes and 14 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $31.8M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $15M sold.
- 92 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q2 2023, up from 74 in Q1 2023.
- Funds reported $387M of Tarsus Pharmaceuticals stock for Q2 2023, up 54% quarter-over-quarter.
- 26 funds opened new Tarsus Pharmaceuticals positions in Q2 2023 and 8 closed out, a net change of +18 holders.
- The largest Tarsus Pharmaceuticals buyer in Q2 2023 was Cowen and Company, an estimated $31.8M added.
- The largest Tarsus Pharmaceuticals seller in Q2 2023 was TimesSquare Capital Management, an estimated $15M sold.
Based on aggregated 13F filings for Q2 2023.